310. Congenital anomalies syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 11 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
Drugs and their primary sponsors and trial info
Antioxidants
University of Colorado, Denver
2008 Phase 2 NCT01773278 United States;
Cholesterol
University of Colorado, Denver
2008 Phase 2 NCT01773278 United States;
Cholesterol supplementation
Oregon Health and Science University
2011 - NCT01356420 United States;
Cholic Acid
University of Nebraska
2021 Phase 1/Phase 2 NCT03720990 United States;
Crystalline cholesterol oil-based suspension
Boston Children’s Hospital
1998 Phase 1/Phase 2 NCT00272844 United States;
DHC
Obstetrics and Gynecology Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000035477 China;
Egg substitute, without cholesterol
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005 Phase 2 NCT00114634 United States;
Egg yolk preparation with cholesterol
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005 Phase 2 NCT00114634 United States;
Gold
Obstetrics and Gynecology Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000035477 China;
Lactose
Oregon Health and Science University
2011 - NCT01434745 United States;
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States;
N-acetyl cysteine
Johns Hopkins University
2022 Phase 2 NCT04381897 United States;
OraPlus
Forbes Porter, M.D.
2003 Phase 2 NCT00064792 United States;
Simvastatin
Oregon Health and Science University
2011 - NCT01434745 United States;
Simvastatin Susp.
Forbes Porter, M.D.
2003 Phase 2 NCT00064792 United States;
University of Colorado, Denver
2008 Phase 2 NCT01773278 United States;
Cholesterol
University of Colorado, Denver
2008 Phase 2 NCT01773278 United States;
Cholesterol supplementation
Oregon Health and Science University
2011 - NCT01356420 United States;
Cholic Acid
University of Nebraska
2021 Phase 1/Phase 2 NCT03720990 United States;
Crystalline cholesterol oil-based suspension
Boston Children’s Hospital
1998 Phase 1/Phase 2 NCT00272844 United States;
DHC
Obstetrics and Gynecology Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000035477 China;
Egg substitute, without cholesterol
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005 Phase 2 NCT00114634 United States;
Egg yolk preparation with cholesterol
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2005 Phase 2 NCT00114634 United States;
Gold
Obstetrics and Gynecology Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000035477 China;
Lactose
Oregon Health and Science University
2011 - NCT01434745 United States;
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States;
N-acetyl cysteine
Johns Hopkins University
2022 Phase 2 NCT04381897 United States;
OraPlus
Forbes Porter, M.D.
2003 Phase 2 NCT00064792 United States;
Simvastatin
Oregon Health and Science University
2011 - NCT01434745 United States;
Simvastatin Susp.
Forbes Porter, M.D.
2003 Phase 2 NCT00064792 United States;